secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0000950170-25-112973
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints
--------------------------------------------------------------------------------

- MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.
- Phase 2b study in 198 adults with moderate-to-severe GAD met primary and key secondary endpoints; dose-response demonstrated.
- MM120 was well-tolerated; adverse events mild-to-moderate, transient, consistent with LSD effects.
- FDA granted Breakthrough Therapy Designation for MM120 in GAD; Phase 3 trials (Voyage, Panorama, Emerge) enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/0000950170-25-112973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/mnmd-20250904.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer